145 related articles for article (PubMed ID: 16412348)
21. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial.
Conter V; Valsecchi MG; Silvestri D; Campbell M; Dibar E; Magyarosy E; Gadner H; Stary J; Benoit Y; Zimmermann M; Reiter A; Riehm H; Masera G; Schrappe M
Lancet; 2007 Jan; 369(9556):123-31. PubMed ID: 17223475
[TBL] [Abstract][Full Text] [Related]
22. Improvement in treatment of childhood acute lymphoblastic leukemia: a 10-year study by the Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T
Int J Hematol; 1994 Feb; 59(2):99-112. PubMed ID: 8018909
[TBL] [Abstract][Full Text] [Related]
23. Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China.
Gao YJ; Lu FJ; Wang HS
J Pediatr Hematol Oncol; 2006 Dec; 28(12):798-802. PubMed ID: 17164648
[TBL] [Abstract][Full Text] [Related]
24. [Long-term follow-up of childhood low-risk ALL patients treated with SCMC-ALL-2005 protocol].
Hu WT; Xue HL; Chen J; Pan C; Shen SH; Zhou M; Ye QD; Jiang H; Luo CY; Tang YJ; Wang JM; Gu LJ; Tang JY
Zhonghua Xue Ye Xue Za Zhi; 2013 Oct; 34(10):834-8. PubMed ID: 24171955
[TBL] [Abstract][Full Text] [Related]
25. [Failure of treatment and protocol compliance in patients with acute lymphoblastic leukemia].
Tang JY; Xue HL; Gu LJ; Chen J; Pan C; Chen J; Wang YP; Ye H; Dong L; Zou JY
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):490-3. PubMed ID: 16083545
[TBL] [Abstract][Full Text] [Related]
26. Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: a challenge for limited health resource countries.
Tantawy AA; El-Rashidy FH; Ragab IA; Ramadan OA; El-Gaafary MM
Hematology; 2013 Jul; 18(4):204-10. PubMed ID: 23394310
[TBL] [Abstract][Full Text] [Related]
27. Results of Treating Childhood Acute Lymphoblastic Leukemia in a Low-middle Income Country: 10 Year Experience in Northeast Mexico.
Jaime-Pérez JC; López-Razo ON; García-Arellano G; Pinzón-Uresti MA; Jiménez-Castillo RA; González-Llano O; Gómez-Almaguer D
Arch Med Res; 2016 Nov; 47(8):668-676. PubMed ID: 28476194
[TBL] [Abstract][Full Text] [Related]
28. ALL-BFM 95 treatment in Turkish children with acute lymphoblastic leukemia--experience of a single center.
Kocak U; Gursel T; Kaya Z; Aral YZ; Albayrak M; Keskin EY; Belen B; Isık M; Oner N
Pediatr Hematol Oncol; 2012 Mar; 29(2):130-40. PubMed ID: 22376016
[TBL] [Abstract][Full Text] [Related]
29. [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
Kwiecińska K; Balwierz W; Moryl-Bujakowska A; Wachowiak J; Derwich K; Matysiak M; Pawelec K; Chybicka A; Dobaczewski G; Kowalczyk JR; Wiśniewska-Slusarz H; Sońta-Jakimczyk D; Szczepański T; Tomaszewska R; Wysocki M; Styczyński J; Balcerska A; Płoszyńska A
Przegl Lek; 2010; 67(6):350-4. PubMed ID: 21344760
[TBL] [Abstract][Full Text] [Related]
30. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
31. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
[TBL] [Abstract][Full Text] [Related]
32. [Childhood acute lymphoblastic leukemia in Norway 1992-2000].
Kolmannskog S; Flaegstad T; Helgestad J; Hellebostad M; Zeller B; Glomstein A
Tidsskr Nor Laegeforen; 2007 May; 127(11):1493-5. PubMed ID: 17551551
[TBL] [Abstract][Full Text] [Related]
33. [Long-term efficacy of CAMSBDH-ALL chemotherapy protocol for the treatment of childhood acute lymphoblastic leukemia].
Chen XJ; Zou Y; Chen YM; Yang WY; Wang SC; Guo Y; Zhang L; Ruan M; Liu XM; Liu F; Liu TF; Zhang JY; Qi BQ; Chang LX; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Oct; 16(10):1019-24. PubMed ID: 25344183
[TBL] [Abstract][Full Text] [Related]
34. [Outcome of childhood high-risk acute lymphoblastic leukemia treated with the ALL-BFM 95 protocol].
Ruan YS; Wu XD; Feng XQ; He YL; Zhang YM; Pei FY; Li CF
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Apr; 17(4):327-31. PubMed ID: 25919549
[TBL] [Abstract][Full Text] [Related]
35. Acute lymphoblastic leukemia in young adults: two chemotherapeutic protocols for the treatment of 46 patients.
Ho CL; Chen YC; Kao WY; Chao TY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):45-52. PubMed ID: 10645050
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
37. Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.
Yetgin S; Tuncer MA; Cetin M; Gümrük F; Yenicesu I; Tunç B; Oner AF; Toksoy H; Koç A; Aslan D; Ozyürek E; Olcay L; Atahan L; Tunçbilek E; Gürgey A
Leukemia; 2003 Feb; 17(2):328-33. PubMed ID: 12592331
[TBL] [Abstract][Full Text] [Related]
38. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).
Kamps WA; Bökkerink JP; Hakvoort-Cammel FG; Veerman AJ; Weening RS; van Wering ER; van Weerden JF; Hermans J; Slater R; van den Berg E; Kroes WG; van der Does-van den Berg A
Leukemia; 2002 Jun; 16(6):1099-111. PubMed ID: 12040440
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
40. [Experiences with modified BFM protocols in the treatment of children with acute lymphoblastic leukemia (ALL) in East Germany 1981-1991].
Zintl F; Malke H; Reimann M; Hermann J; Domula M; Dörffel W; Eggers G; Exadaktylos P; Hilgenfeld E; Kotte W
Klin Padiatr; 1992; 204(4):221-9. PubMed ID: 1518257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
